FOI 9563 – Q4

Of the myelofibrosis (ICD10 D47.4) patients receiving the following treatments in the past 6 months, please indicate how many were receiving their first systemic therapy

(First systemic therapy = patient has not previously received any drug treatment for myelofibrosis, including hydroxycarbamide, interferon therapy, JAK inhibitors, or other systemic therapy. Excludes a watch and wait approach.)

Treatment	First systemic therapy	Received prior systemic therapy
Ruxolitinib (Jakavi)	Less than 5	10
Fedratinib (Inrebic)	0	Less than 5
Momelotinib (Omjjara)	Less than 5	6